Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost

Executive Summary

Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced

You may also be interested in...



Tysabri price jumps

The price of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) upon relaunch in July will be 20.8% higher than when it was first approved in November 2004, according to information on Elan's website. Tysabri's new wholesale acquisition cost will be $2,184.62 per vial compared to $1,808 in 2004. FDA reapproved natalizumab June 5 with an extensive risk management program to prevent cases of progressive multifocal leukoencephalopathy. Biogen/Elan have attributed higher pricing to additional costs associated with administering the risk management plan as well as the inclusion of new efficacy data in labeling (1"The Pink Sheet" June 12, 2006, p. 8)...

Tysabri price jumps

The price of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) upon relaunch in July will be 20.8% higher than when it was first approved in November 2004, according to information on Elan's website. Tysabri's new wholesale acquisition cost will be $2,184.62 per vial compared to $1,808 in 2004. FDA reapproved natalizumab June 5 with an extensive risk management program to prevent cases of progressive multifocal leukoencephalopathy. Biogen/Elan have attributed higher pricing to additional costs associated with administering the risk management plan as well as the inclusion of new efficacy data in labeling (1"The Pink Sheet" June 12, 2006, p. 8)...

Tysabri Out Of Remission; Returns With Updated Indication, Risk Management

The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy

Related Content

UsernamePublicRestriction

Register

PS047285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel